Compare Amplify Cybersecurity ETF (HACK) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amplify Cybersecurity ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Amplify Cybersecurity ETF trades at $122 (market cap $3.56B), while Spyre Therapeutics Inc. Common Stock trades at $78.63 (market cap $7.52B). The key difference: Spyre Therapeutics Inc. Common Stock is far larger — about 2.1× Amplify Cybersecurity ETF's market cap, and Amplify Cybersecurity ETF is trading nearer its 52-week high, Spyre Therapeutics Inc. Common Stock nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Amplify Cybersecurity ETF for 27 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| HACK | SYRE | |
|---|---|---|
Market Cap | $3.56B | $7.52B |
Volume | 331,197 | 1,441,031 |
Sector | Sector/Thematic | Health |
52-Week High | $130.76 | $108.92 |
52-Week Low | $70.69 | $22.18 |
Typical Hold Time | 27 Days | 0 Days |
Enterprise Value | — | $6.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HACK trades at $127.09, down 0.12% on the day, but maintains a bullish technical stance with moving averages signaling strength and momentum indicators like ADX showing strong trend confirmation. The ETF recently hit a 52-week high, driven by AI safety concerns and rising cybersecurity demand, though short interest has surged significantly, indicating mixed sentiment. Financial ratios are not applicable as this is an ETF tracking a basket of cybersecurity stocks.
The outlook for HACK is supported by structural growth in cybersecurity spending, particularly from AI-driven threats, but faces risks from elevated short interest and potential sector rotation. Upside depends on continued sector outperformance, while downside risks include profit-taking after strong gains and broader tech volatility.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Amplify Cybersecurity ETF
HACK provides diversified exposure to the global cybersecurity industry. It invests across the full value chain, including hardware, software, and consulting services, with key holdings in firms like Broadcom, Cisco, and Palo Alto Networks.
Read more on HACK →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
